多中心随机CABASTY试验中双周与三周卡巴他赛方案对老年转移性去势抵抗性前列腺癌患者疼痛与健康相关生活质量的影响
CABASTY研究显示,在老年转移性去势抵抗性前列腺癌(mCRPC)患者中,双周卡巴他赛(CBZ)16 mg/m²方案与三周CBZ 25 mg/m²方案相比,疼痛进展时间、首次阿片类药物使用时间及FACT-P总分恶化时间均无显著差异,但双周组部分不良事件发生时间显著延长,健康相关生活质量无显著差异。
核心结论
- 双周CBZ16方案与标准三周CBZ25方案相比,健康相关生活质量无显著差异,且部分不良事件发生时间延迟。
研究设计与样本
- 多中心随机CABASTY试验(NCT02961257),来自25个中心共196例患者按1:1随机,按年龄和G8评分分层,分为双周CBZ16(卡巴他赛16 mg/m²)实验组或三周CBZ25(卡巴他赛25 mg/m²)对照组。
- 疼痛分析可评估141例患者,健康相关生活质量分析可评估160例患者。
主要发现
- 双周CBZ16组部分不良事件发生时间显著长于三周CBZ25组。
临床怎么用
- 作者认为,这些结果可能增加医疗保健提供者在因化疗被拒绝的老年mCRPC患者中使用卡巴他赛的信心。
局限性
- 疼痛分析可评估患者为141例,健康相关生活质量分析可评估患者为160例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The CABASTY study showed that more frequent administration of a lower dose of cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without compromising efficacy. Here, we investigated the impact of a biweekly CBZ schedule on patient-reported pain and health-related quality of life (HRQoL). METHODS: We randomized 196 patients from 25 centers (1:1, stratified by age and G8 score) to the biweekly CBZ16 (CBZ 16 mg/m2) experimental arm or the triweekly CBZ25 (CBZ 25 mg/m2) control arm (CABASTY study, NCT02961257). We assessed pain using the Numeric Pain Rating Scale and HRQoL using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. KEY FINDINGS AND LIMITATIONS: A total of 141 patients were available for a pain and 160 for an HRQoL analysis. Median time to pain progression (stratified hazard ratio [HR]: 1.7, confidence interval [CI]: 0.67-4.22, p = 0.3) and median time to first opiate use (stratified HR: 1.05, CI: 0.44-2.55, p = 0.9) did not differ between arms. We did not see a significant difference in median time to deterioration of FACT-P total score between treatments (stratified HR: 0.88, CI: 0.47-1.7, p = 0.7). Interestingly, the time to onset of several adverse events was significantly longer in the biweekly CBZ16 group. CONCLUSIONS AND CLINICAL IMPLICATIONS: HRQoL did not significantly differ between the biweekly CBZ16 and the standard schedule. Additionally, onset of some adverse events was delayed. These results may increase health care providers' confidence in using CBZ in older patients with mCRPC who are denied chemotherapy. PATIENT SUMMARY: Androgen receptor pathway inhibitors are often preferred to taxane chemotherapy as a treatment of second or subsequent line in older metastatic castration-resistant prostate cancer patients due to more frequent treatment-related toxicities. Here, we showed that quality of life and pain did not differ significantly with an adapted schedule of cabazitaxel (CBZ), compared with the standard regimen. This CBZ schedule could increase eligibility of older patients for chemotherapy.
引用
- Oudard S, Tran Y, Helissey C, et al. Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial. Eur Urol Oncol. 2024. PMID: 39143002. doi:10.1016/j.euo.2024.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。